Jay Olson

Stock Analyst at Oppenheimer

(4.17)
# 504
Out of 5,044 analysts
247
Total ratings
45.45%
Success rate
16.62%
Average return

Stocks Rated by Jay Olson

iBio, Inc.
Oct 21, 2025
Initiates: Outperform
Price Target: $5
Current: $1.39
Upside: +259.71%
Madrigal Pharmaceuticals
Oct 10, 2025
Maintains: Outperform
Price Target: $500$590
Current: $429.18
Upside: +37.47%
Ionis Pharmaceuticals
Oct 8, 2025
Maintains: Outperform
Price Target: $84$90
Current: $73.57
Upside: +22.33%
Immuneering
Sep 25, 2025
Maintains: Outperform
Price Target: $21$30
Current: $6.49
Upside: +362.25%
Bicycle Therapeutics
Aug 11, 2025
Maintains: Outperform
Price Target: $48$44
Current: $8.22
Upside: +435.28%
Mind Medicine (MindMed)
Aug 4, 2025
Reinstates: Outperform
Price Target: $25
Current: $12.87
Upside: +94.25%
Atai Life Sciences
Jul 29, 2025
Initiates: Outperform
Price Target: $14
Current: $5.96
Upside: +134.90%
Praxis Precision Medicines
Jul 8, 2025
Maintains: Outperform
Price Target: $97$115
Current: $199.33
Upside: -42.31%
ACADIA Pharmaceuticals
Jun 26, 2025
Maintains: Perform
Price Target: $19$22
Current: $22.62
Upside: -2.74%
Prothena Corporation
May 27, 2025
Downgrades: Perform
Price Target: n/a
Current: $10.54
Upside: -
Initiates: Outperform
Price Target: $65
Current: $4.72
Upside: +1,277.12%
Maintains: Outperform
Price Target: $80$65
Current: $2.34
Upside: +2,677.78%
Maintains: Outperform
Price Target: $15$13
Current: $2.58
Upside: +403.88%
Maintains: Outperform
Price Target: $70$75
Current: $58.17
Upside: +28.93%
Upgrades: Outperform
Price Target: $90
Current: $60.92
Upside: +47.73%
Maintains: Outperform
Price Target: $50$42
Current: $16.92
Upside: +148.23%
Downgrades: Perform
Price Target: $41$33
Current: $40.08
Upside: -17.65%
Maintains: Outperform
Price Target: $60$40
Current: $13.96
Upside: +186.53%
Maintains: Outperform
Price Target: $80$20
Current: $2.56
Upside: +681.25%
Initiates: Outperform
Price Target: $30
Current: $8.24
Upside: +264.08%
Maintains: Outperform
Price Target: $17$20
Current: $8.59
Upside: +132.83%
Maintains: Outperform
Price Target: $270$255
Current: $149.13
Upside: +70.99%
Maintains: Outperform
Price Target: $81$82
Current: $91.65
Upside: -10.53%
Maintains: Outperform
Price Target: $9$10
Current: $7.16
Upside: +39.66%
Reiterates: Outperform
Price Target: $138
Current: $34.93
Upside: +295.08%
Assumes: Outperform
Price Target: $8
Current: $1.92
Upside: +316.67%
Maintains: Outperform
Price Target: $380
Current: $292.09
Upside: +30.10%
Maintains: Outperform
Price Target: $216$219
Current: $147.38
Upside: +48.60%
Maintains: Perform
Price Target: $12
Current: $3.17
Upside: +278.55%
Maintains: Outperform
Price Target: $18
Current: $4.66
Upside: +286.27%
Maintains: Outperform
Price Target: $10
Current: $1.11
Upside: +804.98%
Maintains: Outperform
Price Target: $102$95
Current: $64.17
Upside: +48.04%
Initiates: Outperform
Price Target: $25
Current: $1.56
Upside: +1,502.56%
Maintains: Outperform
Price Target: $9
Current: $1.59
Upside: +466.04%
Maintains: Perform
Price Target: n/a
Current: $14.84
Upside: -
Maintains: Outperform
Price Target: $1,200$500
Current: $1.86
Upside: +26,781.72%
Maintains: Perform
Price Target: $25$21
Current: $10.47
Upside: +100.57%
Downgrades: Perform
Price Target: n/a
Current: $2.45
Upside: -
Maintains: Outperform
Price Target: $70$84
Current: $18.25
Upside: +360.27%
Upgrades: Outperform
Price Target: n/a
Current: $1.25
Upside: -